Grant: Master's Award: Canada Graduate Scholarships
McGill University
$17,500.00
AT1R Biased Signaling
EF 2022-23
Résumé
The causes of hypertension and its associated cardiovascular risks can be attributed to the hormone Angiotensin II (Ang II). Ang II regulates the body's blood volume and vascular resistance by binding to its associated receptor, angiotensin II type 1 receptor (AT1R). When AngII binds to AT1R this elicits a downstream signaling cascade involving a certain type of protein called a G protein because AT1R is part of the G-protein coupled receptor (GPCR) family of membrane receptors. Conventional drugs used to treat hypertension mainly block the activity of the AT1R, therefore, preventing the activation of AT1R's downstream signaling pathways. These anti-hypertensive drugs are efficacious, however, they offer limited benefits for improving one's cardiovascular health. This is because recent studies have shown that some pathways activated by AT1R signaling are cardio-protective, thus, if all of AT1R's signaling pathways are attenuated the protective effects of these pathways are lost. Thus, developing a biased drug that targets specific GPCR-mediated pathways, while simultaneously inhibiting other pathways, may confer new pharmacological benefits and cardio-protective effects in many patients. Moreover, my objective is to to explore and identify key regions of the AT1R that induce biased signaling of the AT1R to explain the rules governing the selectivity of the signaling pathways involved with AT1R. Furthermore, given the high demand for a novel drug that is able to simultaneously offer anti-hypertensive and cardio-protective effects, understanding the signaling pathways involved with AT1R and their contribution to pathophysiological outcomes will give important insights towards the development of an efficacious therapeutic against AT1R to treat hypertension.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
486044
Name
Verma Evanee L
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
AT1R Biased Signaling
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Allosteric Regulation; Allostery; Angiotensin Ii; Biased Signalling; Cardiovascular Diseases; G Protein-Coupled Receptors (Gpcr); Hypertension; Mutagenesis; Peptide; Small Molecule
Abstract
The causes of hypertension and its associated cardiovascular risks can be attributed to the hormone Angiotensin II (Ang II). Ang II regulates the body's blood volume and vascular resistance by binding to its associated receptor, angiotensin II type 1 receptor (AT1R). When AngII binds to AT1R this elicits a downstream signaling cascade involving a certain type of protein called a G protein because AT1R is part of the G-protein coupled receptor (GPCR) family of membrane receptors. Conventional drugs used to treat hypertension mainly block the activity of the AT1R, therefore, preventing the activation of AT1R's downstream signaling pathways. These anti-hypertensive drugs are efficacious, however, they offer limited benefits for improving one's cardiovascular health. This is because recent studies have shown that some pathways activated by AT1R signaling are cardio-protective, thus, if all of AT1R's signaling pathways are attenuated the protective effects of these pathways are lost. Thus, developing a biased drug that targets specific GPCR-mediated pathways, while simultaneously inhibiting other pathways, may confer new pharmacological benefits and cardio-protective effects in many patients. Moreover, my objective is to to explore and identify key regions of the AT1R that induce biased signaling of the AT1R to explain the rules governing the selectivity of the signaling pathways involved with AT1R. Furthermore, given the high demand for a novel drug that is able to simultaneously offer anti-hypertensive and cardio-protective effects, understanding the signaling pathways involved with AT1R and their contribution to pathophysiological outcomes will give important insights towards the development of an efficacious therapeutic against AT1R to treat hypertension.
Competitiondate
202212
Approvedterm2
1 yr 0 mth
Pinamesdelim
Verma, Evanee L
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~